San Jose, CA, 25 October 2022 – Complete Genomics, part of MGI, celebrates the US commercial launch of its DNBSEQ™ sequencing product line at the American Society of Human Genetics (ASHG) Annual Meeting, taking place from 25–29 October in Los Angeles. MGI is a global life science tool provider delivering lab automation and NGS sequencing platforms worldwide.
Complete Genomics offers a complete NGS solution, including sample extraction, library preparation, automation systems, sequencing platforms, and bioinformatics. Though new to the US market, MGI has been providing NGS sequencers since 2017, with thousands of instruments installed globally. Its latest innovation, DNBSEQ™, is available across all sequencing platforms, eliminating index hopping and clonal errors during sequencing. This makes sequencing more accurate, flexible, and affordable, enhancing throughput and accelerating scientific discoveries.
At ASHG, Complete Genomics is showcasing the DNBSEQ-E25*, DNBSEQ-G400*, DNBSEQ-T7*, and DNBSEQ-T10×4* at the MGI booth (#1803). The DNBSEQ-G400* was introduced in the US in August 2022, with the first units installed in customers’ labs within a week. The DNBSEQ-G400* is a medium-throughput benchtop sequencer (up to 1,440 Gb daily), offering flexible options for research: one or two flow cells, two flow cell types (550M vs 1,800M reads), and read lengths ranging from SE50 to SE400 or PE300.
Upcoming 2023 Sequencers
Throughout 2023, Complete Genomics will continue to expand its product line for labs of all sizes, including:
- DNBSEQ-T7* – An ultra-high-throughput sequencer with four independent flow cells, enabling over 20,000 30X WGS genomes per year. Available from January 2023.
- DNBSEQ-T10×4* – The highest-throughput platform, delivering up to 18 Tb per day and equipped with a robotic arm to streamline sequencing. Available from January 2023.
- DNBSEQ-E25* – A low-throughput portable sequencer (up to 7.5 Gb daily) with built-in bioinformatics. Simple setup allows operation in ten minutes, delivering sample-to-FASTQ results in 20 hours. Launching in Q2 2023.
For full sequencer specifications, visit the Complete Genomics website.
Industry Partnerships
The DNBSEQ-G400* launch has attracted strong interest within the scientific community and enabled partnerships with leading life science companies to demonstrate high data quality and provide advanced NGS solutions. Key partners include:
- Agilent Technologies
- Bio-Rad Laboratories, Inc.
- BioSkryb
- Gencove
- New England Biolabs (NEB)
- Qiagen
- Roche
- Sentieon
- Sophia Genetics
- TwinStrand Biosciences
- Watchmaker Genomics
Complete Genomics will also present customer experiences at the industry education session on 28 October, 7:00–8:00 am. Loma Linda University School of Medicine will discuss “Benchmarking Study of Next-Gen Sequencing Using NASA Spaceflight Mouse Brain Samples,” and Sentieon will present “Accurate Small Variant Calling by DNAscope on MGI DNBSEQ-G400* Sequencing Platform.”
MGI prioritises data security. All DNBSEQ™ platforms can operate as standalone systems from sample to result without network connection, ensuring complete control over sensitive data.
About Complete Genomics
Based in San Jose, California, Complete Genomics has been a research and development centre of excellence since June 2018. Its demo lab features all sequencers and automation equipment for customer visits, and the facility serves as the supply centre for the Americas, ensuring timely delivery of systems and products. The DNBSEQ-G400* platform marked Complete Genomics’ first US release in August 2022.
*Unless otherwise indicated, StandardMPS and CoolMPS sequencing reagents and associated sequencers are not available in Germany, Spain, the UK, Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania. StandardMPS products cannot be ordered in the USA before 1 January 2023. DNBSEQ-E25*, DNBSEQ-G400*, DNBSEQ-T7*, and DNBSEQ-T10×4* displayed at ASHG are non-functional models for exhibition purposes only.
*Products are for Research Use Only. Not for diagnostic procedures.*
